Introducing a Gene Knockout Directly Into the Amastigote Stage of Trypanosoma cruzi Using the CRISPR/Cas9 System
July 31st, 2019
8.3K views
Here, we describe a protocol to introduce a gene knockout into the extracellular amastigote of Trypanosoma cruzi, using the CRISPR/Cas9 system. The growth phenotype can be followed up either by cell counting of axenic amastigote culture or by proliferation of intracellular amastigotes after host cell invasion.
Overview
This article describes a protocol for introducing a gene knockout into the extracellular amastigote of Trypanosoma cruzi using the CRISPR/Cas9 system. The growth phenotype can be monitored through cell counting or by assessing the proliferation of intracellular amastigotes post-host cell invasion.
Key Study Components
Area of Science
- Neuroscience
- Microbiology
- Genetics
Background
- Amastigotes are obligate intracellular parasites, making experimental manipulation challenging.
- The culturing technique allows for temporary replication outside of host cells.
- This method enables direct experimentation on a clinically relevant stage of T. cruzi.
- Yukie Akutsu, a technician, demonstrates the procedure.
Purpose of Study
- To develop a reliable method for gene editing in T. cruzi amastigotes.
- To facilitate the study of the growth phenotype of the parasite.
- To enhance understanding of T. cruzi biology and potential therapeutic targets.
Methods Used
- Maintain a host-parasite co-culture as per manuscript directions.
- Collect supernatant for quality assessment under a microscope.
- Perform a swim-out procedure to isolate trypomastigotes if extracellular amastigotes are present.
- Utilize the CRISPR/Cas9 system for gene knockout.
Main Results
- Successful introduction of gene knockout into T. cruzi amastigotes.
- Demonstrated growth phenotype tracking through various methods.
- Validated culturing technique for studying amastigotes outside host cells.
- Provided a framework for future research on T. cruzi biology.
Conclusions
- The protocol enables effective gene editing in T. cruzi amastigotes.
- This approach can lead to new insights into the biology of the parasite.
- Future studies can build on this methodology to explore therapeutic avenues.
Frequently Asked Questions
What is the significance of studying T. cruzi amastigotes?
Studying T. cruzi amastigotes is crucial for understanding the lifecycle and pathogenicity of the parasite, which causes Chagas disease.
How does the CRISPR/Cas9 system work in this context?
The CRISPR/Cas9 system allows for targeted gene editing, enabling researchers to knock out specific genes in the amastigotes to study their functions.
What are the challenges of working with T. cruzi?
The main challenge is that amastigotes are intracellular, making them difficult to study outside of host cells.
What methods are used to assess the growth phenotype?
Growth phenotype can be assessed through cell counting of axenic cultures or by monitoring intracellular proliferation after host cell invasion.
Who demonstrated the procedure in the study?
The procedure was demonstrated by Yukie Akutsu, a technician from the institute.
Executive Industry Relevance
Direct CRISPR/Cas9-mediated gene knockout in the amastigote stage of Trypanosoma cruzi enables precise target validation in the clinically relevant mammalian stage. This approach bypasses developmental stage transitions, reducing biological ambiguity and increasing predictive confidence for anti-parasitic drug discovery. The method supports risk-adjusted portfolio decisions by clarifying gene essentiality in disease-relevant systems.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct interrogation of gene essentiality in the amastigote stage, the primary target for Chagas disease therapies.
- Supports functional validation of candidate drug targets in a disease-relevant context.
- Reduces confounding effects from stage differentiation, increasing mechanistic clarity.
- Facilitates rapid triage of targets based on phenotypic knockout outcomes.
Screening & Assay Development
- Provides a validated axenic amastigote system for standardized phenotypic assays.
- Enables reproducible quantitative measurement of amastigote growth and viability post-knockout.
- Supports scalable screening of gene function and compound effects in the relevant parasite stage.
- Improves assay readiness for downstream compound evaluation targeting amastigote biology.
Translational & Preclinical Research
- Aligns gene function studies with the intracellular lifecycle stage responsible for disease pathology.
- Enables continuity from target validation through preclinical efficacy models by focusing on the amastigote stage.
- Supports translational biomarker identification by linking gene knockout phenotypes to host cell infection outcomes.
- De-risks advancement decisions by providing direct evidence of target impact in the mammalian stage.
Pipeline & Workflow Integration
This method integrates into the discovery pipeline from early target validation through preclinical model development, focusing on the amastigote stage for maximal disease relevance.
- Discovery Biology: Supports hypothesis testing and pathway clarification by enabling gene knockout directly in amastigotes.
- Screening: Delivers reproducible, quantitative readouts of amastigote viability and replication post-editing.
- Analytics: Provides cell count and infection rate measurements to compare knockout and control conditions.
- Translational Research: Links in vitro knockout phenotypes to intracellular infection outcomes, supporting biomarker alignment.
- Enterprise Reuse: Establishes a reusable platform for stage-specific genetic manipulation and phenotypic analysis in T. cruzi.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by focusing on the disease-relevant amastigote stage.
- Operational Value: Standardizes gene editing and phenotypic analysis workflows for reproducibility and scalability.
- Strategic Value: Enables informed go/no-go decisions by clarifying target essentiality and reducing late-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization of targets and compounds for Chagas disease drug discovery.
Implementation Considerations
- Requires expertise in parasite culturing, CRISPR/Cas9 gene editing, and phenotypic assay design.
- Needs access to electroporation equipment, fluorescence microscopy, and cell culture infrastructure.
- Demands cross-team standardization of axenic amastigote preparation and viability assays.
- May require adaptation for different T. cruzi strains or host cell models.
- Axenic amastigote culture is temporally limited, necessitating precise timing for experimental workflows.
Biopharma FAQs
Why does null hypothesis testing matter for amastigote gene knockout?
Null hypothesis testing in amastigote gene knockout experiments enables objective assessment of whether gene disruption significantly impacts parasite growth or infectivity. This statistical rigor is essential for validating target essentiality in the disease-relevant stage and informing portfolio advancement decisions.
How does independent variable isolation fit the CRISPR/Cas9 knockout workflow?
Isolating the gene of interest as the independent variable ensures that observed phenotypic changes in amastigote growth or infection are attributable to the specific knockout. This isolation strengthens mechanistic de-risking and supports confident target validation in the discovery pipeline.
What do quantitative cell counts of axenic amastigotes enable?
Quantitative cell counts provide reproducible, objective measurements of amastigote viability and proliferation post-knockout. These outputs enable direct comparison between experimental and control groups, supporting robust assessment of gene function.
Why are replication requirements critical for cross-functional collaboration?
Replication of knockout phenotypes across independent experiments and teams ensures data reliability and reproducibility. This is vital for cross-functional collaboration, enabling consistent interpretation and downstream decision-making in R&D workflows.
What statistical analysis capabilities are required before implementing knockout phenotyping?
Statistical analysis capabilities are needed to evaluate significance in cell count differences and infection rates between knockout and control groups. These analyses underpin data-driven decisions and support rigorous target validation in biopharma pipelines.
Chapters in this video
0:04
Title
0:35
Differentiation of Trypomastigotes into Extracellular Amastigotes
1:54
Electroporation of Extracellular Amastigotes
3:01
Monitoring the Growth of Knockout Cells
4:35
Results: Growth Monitoring and Phenotypic Differences of Knockout Parasites
5:41
Conclusion
